AbbVie's Rinvoq Gains Early Traction in Giant Cell Arteritis Market, Expanding Options for Rheumatologists

Core Insights - Rheumatologists express high satisfaction with AbbVie's Rinvoq (upadacitinib) following its approval for giant cell arteritis (GCA), highlighting anticipated efficacy, steroid-sparing benefits, and convenient oral administration as key factors for adoption [1] - Nearly all specialists are aware of Rinvoq's approval, with 40% already prescribing it for GCA patients, indicating a favorable early adoption compared to previous launches in ankylosing spondylitis and psoriatic arthritis [1] - Rinvoq is being initiated in the first-line advanced therapy setting for nearly half of current patients, reflecting an unmet need for effective oral alternatives [1] Adoption and Market Dynamics - Most rheumatologists foresee expanding Rinvoq's use in GCA, projecting peak adoption could reach nearly one-third of patients once fully established [2] - Despite safety concerns and payer hurdles, early data suggest Rinvoq is on track to become a significant competitor in the GCA market and may influence treatment decisions in polymyalgia rheumatica (PMR) [2] - Rinvoq's introduction is shifting perceptions around Genentech's Actemra (tocilizumab), with Rinvoq rated higher on convenience, speed of onset, and patient preference for oral administration [1] Safety and Cost Considerations - Physicians cite cardiovascular and thromboembolic risks in older GCA patients as significant safety concerns, alongside challenges related to Medicare coverage and out-of-pocket costs [1] - Despite these concerns, the majority of physicians view Rinvoq's overall risk-benefit profile as favorable, with over half indicating they are likely to recommend the therapy to colleagues [1] Off-Label Use and Future Outlook - One-quarter of rheumatologists anticipate increasing off-label use of Rinvoq in PMR, particularly for patients needing steroid-sparing strategies [1] - Rinvoq's oral administration and JAK1 selectivity are seen as advantages for some patients, although it has not yet been approved for PMR [1]